Pearce IP BioBlast™: w/e 26 Jun 2020

by , | Jun 29, 2020

Significant biosimilar activities this week include

June 20 | The NZ Herald reported a new study by NZ scientists which indicates that transgenic goats are capable of producing milk with high levels of cetuximab.

22 Jun 20 | Ankylosing Spondylitis News reported new data from Germany indicates Simponi® (golimumab) is an effective therapy for people with ankylosing spondylitis and other chronic inflammatory conditions, regardless of pre-treatment with other TNF inhibitors.

25 Jun 20 | Sandoz launched its ‘Biosimilars Generation’ campaign, aimed to help Canadians better understand the benefits of biosimilars, their safety and efficacy, and the opportunities for cost savings.  The campaign includes a new website aimed at supporting and educating Canadians.

25 Jun 20 | Aptevo Therapeutics announced it will receive quarterly “low single digit” fixed royalty payments from Pfizer (Wyeth) for 7 years from the first launch of Ruxience® (biosimilar rituximab).  The original royalty agreement was signed by Trubion Pharmaceuticals which was then acquired by Aptevo’s spin-off Emergent BioSolutions, and Wyeth, in 2016.  The royalty is applied to net sales in the US, EU and Japan.

26 Jun 20 | Samsung Bioepis announced the CHMP has adopted a positive opinion for Aybintio® (biosimilar bevacizumab).

26 Jun 20 | Janssen announced it has discontinued its Ph III LOTUS study of Stelara® (ustekinumab) in Systematic Lupus Erythematosus due to lack of efficacy.

27 Jun 20 | Shanghai Henlius Biotech announced the Investigational New Drug application for HLX14 (biosimilar denosumab) has been approved by China’s NMPA for the treatment of postmenopausal osteoporosis.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.

Our Latest News